Abeona Therapeutics Stock Performance
| ABEO Stock | USD 5.98 0.19 3.28% |
Abeona Therapeutics has a performance score of 2 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.9, which signifies possible diversification benefits within a given portfolio. Abeona Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Abeona Therapeutics is expected to follow. Abeona Therapeutics right now shows a risk of 2.52%. Please confirm Abeona Therapeutics potential upside, rate of daily change, and the relationship between the sortino ratio and skewness , to decide if Abeona Therapeutics will be following its price patterns.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Abeona Therapeutics are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of very healthy technical and fundamental indicators, Abeona Therapeutics is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 3.28 | Five Day Return 2.75 | Year To Date Return 8.14 | Ten Year Return (96.64) | All Time Return (100.00) |
Last Split Factor 1:25 | Last Split Date 2022-07-05 |
1 | Disposition of 496 shares by Omalley Brendan M. of Abeona Therapeutics at 6.02 subject to Rule 16b-3 | 09/20/2024 |
2 | Where are the Opportunities in - Stock Traders Daily | 09/26/2024 |
3 | Disposition of 6388 shares by Joseph Vazzano of Abeona Therapeutics at 5.89 subject to Rule 16b-3 | 09/27/2024 |
4 | Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635 | 10/01/2024 |
5 | Renaissance Technologies LLC Grows Stake in Abeona Therapeutics Inc - MarketBeat | 10/03/2024 |
6 | Disposition of 251 shares by Seshadri Vishwas of Abeona Therapeutics at 6.54 subject to Rule 16b-3 | 10/16/2024 |
7 | Abeona Therapeutics Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration | 10/29/2024 |
8 | Abeona Therapeutics Announces Participation in November Investor Conferences | 11/04/2024 |
9 | Abeona Therapeutics Inc Q3 2024 Earnings Call Highlights Strategic Advances Amid ... | 11/15/2024 |
10 | Earnings call Abeona Therapeutics Q3 2024 results and PZ cell update - Investing.com | 11/22/2024 |
| Begin Period Cash Flow | 14.6 M |
Abeona |
Abeona Therapeutics Relative Risk vs. Return Landscape
If you would invest 574.00 in Abeona Therapeutics on August 25, 2024 and sell it today you would earn a total of 24.00 from holding Abeona Therapeutics or generate 4.18% return on investment over 90 days. Abeona Therapeutics is currently generating 0.094% in daily expected returns and assumes 2.5151% risk (volatility on return distribution) over the 90 days horizon. In different words, 22% of stocks are less volatile than Abeona, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Abeona Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Abeona Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Abeona Therapeutics, and traders can use it to determine the average amount a Abeona Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0374
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | ABEO | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.52 actual daily | 22 78% of assets are more volatile |
Expected Return
| 0.09 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 2 98% of assets perform better |
Based on monthly moving average Abeona Therapeutics is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Abeona Therapeutics by adding it to a well-diversified portfolio.
Abeona Therapeutics Fundamentals Growth
Abeona Stock prices reflect investors' perceptions of the future prospects and financial health of Abeona Therapeutics, and Abeona Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Abeona Stock performance.
| Return On Equity | -1.27 | ||||
| Return On Asset | -0.38 | ||||
| Current Valuation | 173.36 M | ||||
| Shares Outstanding | 43.47 M | ||||
| Price To Earning | 0.11 X | ||||
| Price To Book | 5.68 X | ||||
| Price To Sales | 61.63 X | ||||
| Revenue | 3.5 M | ||||
| Gross Profit | (28 M) | ||||
| EBITDA | (50.57 M) | ||||
| Net Income | (54.19 M) | ||||
| Cash And Equivalents | 20.1 M | ||||
| Cash Per Share | 3.38 X | ||||
| Total Debt | 5.4 M | ||||
| Debt To Equity | 0.42 % | ||||
| Current Ratio | 2.21 X | ||||
| Book Value Per Share | 0.56 X | ||||
| Cash Flow From Operations | (37.01 M) | ||||
| Earnings Per Share | (2.05) X | ||||
| Market Capitalization | 259.96 M | ||||
| Total Asset | 64 M | ||||
| Retained Earnings | (749.52 M) | ||||
| Working Capital | 42.31 M | ||||
| Current Asset | 31.95 M | ||||
| Current Liabilities | 6.51 M | ||||
About Abeona Therapeutics Performance
By examining Abeona Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Abeona Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Abeona Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 304.99 | 487.59 | |
| Return On Tangible Assets | (0.85) | (0.89) | |
| Return On Capital Employed | (0.93) | (0.89) | |
| Return On Assets | (0.85) | (0.89) | |
| Return On Equity | (3.65) | (3.84) |
Things to note about Abeona Therapeutics performance evaluation
Checking the ongoing alerts about Abeona Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Abeona Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 3.5 M. Net Loss for the year was (54.19 M) with loss before overhead, payroll, taxes, and interest of (28 M). | |
| Abeona Therapeutics currently holds about 20.1 M in cash with (37.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.38. | |
| Abeona Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 78.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Earnings call Abeona Therapeutics Q3 2024 results and PZ cell update - Investing.com |
- Analyzing Abeona Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Abeona Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Abeona Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Abeona Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Abeona Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Abeona Therapeutics' stock. These opinions can provide insight into Abeona Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abeona Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Abeona Stock, please use our How to Invest in Abeona Therapeutics guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abeona Therapeutics. If investors know Abeona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abeona Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.05) | Quarterly Revenue Growth (1.00) | Return On Assets (0.38) | Return On Equity (1.27) |
The market value of Abeona Therapeutics is measured differently than its book value, which is the value of Abeona that is recorded on the company's balance sheet. Investors also form their own opinion of Abeona Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Abeona Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abeona Therapeutics' market value can be influenced by many factors that don't directly affect Abeona Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abeona Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abeona Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abeona Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.